The Covid-19 pandemic has caused immense disruption on the health and economic front. While the healthcare sector takes charge to remedy the damage, there are new factors that are greatly impacting financial decisions and overall business viability. As one of the world leaders for clinical trials thanks to its world-class infrastructure, universal healthcare system, and national policies that support the clinical research industry, Thailand is racing to produce a coronavirus vaccine, currently under testing and anticipated to be available for wider use within 2021. This event has enhanced government direction post Covid-19 to advance Thailand's healthcare and life science industry to become a leader in the region supporting the region's anticipated growth as a medical hub.
 
In addition to the accelerated technology and scientific advancement witnessed during Covid-19 pandemic situation, there has been a change in the traditional model of healthcare allowing sophisticated AI-based algorithm and Big Data to remotely diagnose, monitor and treat disease, leading to a shift in health care delivery from hospitals and clinics to patients' homes. The potential of digital and data to reinvent the entire business value chain will create new opportunities for life sciences companies to capture future value through the development of personalized products and services, and end-to-end solutions.
 
Our Speaker: 
Dr. Nares Damrongchai is the Chief Executive Officer of Thailand Center of Excellence for Life Sciences (TCELS), a public organization with a mission to foster the life sciences industry. He is a Committee Member at National Committee on Science and Technology Ethic and is responsible for a study on ethical issues regarding big data and AI. Nares also serves as Co-Chair of Life Science Innovation Forum, APEC's leading initiative on health and health sciences innovation. 
 
He was instrumental in drafting and proposing Thailand's first and second National Biotechnology Policy and National Nanotechnology Policy. Recently he helped to formulate the Biopharmaceuticals part of Thailand's Bioeconomy Policy, the Yothi Medical Innovation District in Bangkok, Medicopolis Digital Health City in Chiang Mai, and Genomic Thailand, an Nation-wide Genomic Program.